<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimalarial drugs: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimalarial drugs: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antimalarial drugs: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Travassos, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Miriam K Laufer, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness  (<a class="graphic graphic_figure graphicRef79113" href="/z/d/graphic/79113.html" rel="external">figure 1</a>). The extent of pre-erythrocytic (hepatic stage) activity for most antimalarial drugs is not well characterized.</p><p>Treatment of the acute blood stage infection is necessary for malaria caused by all malaria species. In addition, for infection due to <em>Plasmodium ovale</em> or <em>Plasmodium vivax</em>, terminal prophylaxis is required with a drug active against hypnozoites (which can remain dormant in the liver for months and, occasionally, years after the initial infection).</p><p>The mechanisms of action, resistance, and toxicities of antimalarial drugs will be reviewed here. Use of these agents for prevention and treatment of malaria is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5722.html" rel="external">"Prevention of malaria infection in travelers"</a> and  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a> and  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a>.)</p><p class="headingAnchor" id="H686648733"><span class="h1">ARTEMISININ DERIVATIVES</span><span class="headingEndMark"> — </span>The artemisinins are derived from the leaves of the Chinese sweet wormwood plant, <em>Artemisia annua</em>. They have been used in China for the treatment of malaria for over 2000 years and came to attention outside of China in the 1970s and 1980s. Artemisinin formulations include artemether, arteether, dihydroartemisinin, and <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a>. They are marketed as part of combination therapy throughout the world.</p><p>Artemisinins appear to act by binding iron, breaking down peroxide bridges, leading to the generation of free radicals that damage parasite proteins [<a href="#rid1">1</a>]. They act rapidly, killing blood stages of all <em>Plasmodium</em> species and reducing the parasite biomass [<a href="#rid2">2</a>]. Artemisinins have the fastest parasite clearance times of any antimalarial [<a href="#rid3">3</a>]. Artemisinins are active against gametocytes, the parasite form that is infectious to mosquitoes, and their use has been associated with reduced malaria transmission when they were introduced in Thailand [<a href="#rid4">4,5</a>].</p><p>Intravenous <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> is first-line therapy for the treatment of severe malaria. It is superior to <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> for treatment of severe malaria with respect to clearing parasitemia and reducing mortality in both children and adults [<a href="#rid6">6,7</a>]. Intravenous artesunate is available for purchase through several major drug distributors [<a href="#rid8">8</a>]. Rectal artesunate is used in remote areas of malaria-endemic countries for stabilizing severely ill patients prior to health facility transport for further management [<a href="#rid9">9</a>].</p><p>Given the short half-life of artemisinins, intravenous therapy must be followed by a longer-acting agent once the patient is able to tolerate oral medication. If used alone (via the parenteral, rectal, or oral route), <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> must be administered for five to seven days. Treatment for less than five days results in recurrent parasitemia several weeks after therapy due to the very short duration of action rather than to artemisinin resistance.</p><p>Individuals with hyperparasitemia treated with intravenous <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> may experience post-treatment hemolysis [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p>Artemisinins are generally well tolerated [<a href="#rid4">4,11,12</a>]. Type 1 hypersensitivity to the artemisinin compounds has been reported (incidence 1:3000) [<a href="#rid13">13</a>]. A large-scale study on the adverse effects of orally administered artemisinins demonstrated transient neurologic abnormalities, including nystagmus and disturbances in balance; these effects resolved without lasting sequelae [<a href="#rid12">12</a>]. Transient neutropenia has been observed in individuals receiving oral <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> at doses higher than that typically prescribed [<a href="#rid14">14</a>].</p><p>There have been concerns about the use of artemisinins during the first trimester of pregnancy. Animal studies have suggested that the artemisinin derivatives may be teratogenic during organogenesis [<a href="#rid15">15,16</a>]. A limited number of women in their first trimester have been studied without evidence of adverse events. In observational studies, artemisinins administered in the first trimester have not been associated with adverse pregnancy outcomes [<a href="#rid17">17,18</a>].</p><p>Hemoglobinopathies (such as alpha-globin chain disorders and sickle cell disease) may alter artemisinin metabolism within infected erythrocytes and thus affect parasite clearance, but this has not been shown to be clinically significant [<a href="#rid19">19,20</a>]. Further study of the metabolism of artemisinins in these populations is needed, particularly in regions such as Southeast Asia, where there is artemisinin resistance and hemoglobinopathies such as hemoglobin E are common.</p><p class="headingAnchor" id="H3466145481"><span class="h2">Artemisinin-based combination therapies</span><span class="headingEndMark"> — </span>In general, artemisinins should not be used as a single agent to prevent emergence of drug resistance and to avoid the need for prolonged therapy. Artemisinin-based combination therapy (ACT) combines the highly effective short-acting artemisinins with a longer-acting partner to protect against artemisinin resistance and to facilitate dosing convenience. ACTs are typically administered for three days and are often available in fixed-dose tablets.</p><p>Six ACTs are recommended by the World Health Organization for the treatment of uncomplicated malaria: <a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">artemether-lumefantrine</a>, artesunate-amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine  (<a class="graphic graphic_table graphicRef107438" href="/z/d/graphic/107438.html" rel="external">table 1</a>) [<a href="#rid21">21,22</a>]. Artemether-lumefantrine is the most widely adopted ACT, followed by artesunate-amodiaquine. Dihydroartemisinin-piperaquine is being widely used in research studies and pilot programs for intermittent treatment and targeted parasite elimination programs.</p><p><a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">Artemether-lumefantrine</a> is best absorbed with fat so should be taken with a meal or fatty drink such as milk. In contrast, dihydroartemisinin-piperaquine should not be taken with a high-fat meal, as this increases piperaquine absorption which may alter cardiac conduction and increase the risk of an arrhythmia [<a href="#rid10">10</a>]. Dihydroartemisinin-piperaquine should not be administered to patients at risk for prolonged QT interval.</p><p>Pyronaridine-artesunate is a newer ACT formulation with similar efficacy to <a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> and artesunate-mefloquine for treatment of uncomplicated <em>P. falciparum</em> malaria [<a href="#rid23">23-25</a>]. Pyronaridine is active against chloroquine-resistant infections, although there has been concern about the emergence of resistance if used as monotherapy [<a href="#rid26">26,27</a>]. Advantages of pyronaridine include its structural dissimilarity to other antimalarial drugs, long shelf-life, and once-daily dosing.</p><p class="headingAnchor" id="H967552234"><span class="h2">Artemisinin resistance</span><span class="headingEndMark"> — </span>Reduced susceptibility to artemisinins, as evidenced by delayed parasite clearance time, has been demonstrated in Southeast Asia but not sub-Saharan Africa [<a href="#rid28">28-31</a>]. Point mutations in the kelch protein K13 are associated with this reduced susceptibility [<a href="#rid30">30,32-34</a>]; the underlying mechanism is not known. Many of these mutations have arisen independently in Southeast Asia, but resistance has also spread within the region [<a href="#rid33">33</a>]. Evidence of artemisinin resistance has emerged in sub-Saharan Africa but is not yet widespread [<a href="#rid35">35,36</a>].</p><p>Decreased susceptibility to artemisinins may increase the likelihood of developing resistance to partner drugs. Dihydroartemisinin-piperaquine treatment failures in Cambodia have occurred where artemisinin resistance is emerging [<a href="#rid37">37-39</a>]. The mechanism for piperaquine resistance has not yet been determined; increased copy numbers of <em>plasmepsin 2</em> and <em>plasmepsin 3</em>, two genes that encode proteases that digest hemoglobin, serve as markers for resistance [<a href="#rid40">40,41</a>]. A novel mutation in the <em>pfcrt</em> gene is also associated with decreased piperaquine sensitivity [<a href="#rid42">42</a>].</p><p>Because the artemisinins are the cornerstone of nearly all new combination therapies, the World Health Organization has called for the banning of all manufacturing and distribution of oral artemisinin monotherapy to deter resistance.</p><p class="headingAnchor" id="H2"><span class="h1">QUINOLINE DERIVATIVES</span><span class="headingEndMark"> — </span>Quinoline derivatives include <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, amodiaquine, <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>, lumefantrine, and halofantrine. These drugs have activity against the erythrocytic stage of infection; primaquine also kills intrahepatic forms and gametocytes  (<a class="graphic graphic_figure graphicRef79113" href="/z/d/graphic/79113.html" rel="external">figure 1</a>). The drugs act by accumulating in the parasite food vacuole and forming a complex with heme that prevents crystallization in the <em>Plasmodium </em>food vacuole. Heme polymerase activity is inhibited, resulting in accumulation of cytotoxic-free heme.</p><p class="headingAnchor" id="H3"><span class="h2">4-aminoquinolines</span></p><p class="headingAnchor" id="H4"><span class="h3">Chloroquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> was the first drug produced on a large scale for treatment and prevention of malaria infection. Chloroquine has activity against the blood stages of <em>P. ovale</em>, <em>Plasmodium malariae</em>, and susceptible strains of <em>P. vivax</em> and <em>Plasmodium falciparum </em>[<a href="#rid43">43</a>]. Widespread resistance in most malaria-endemic countries has led to decline in its use for the treatment of <em>P. falciparum</em>, although it remains effective for treatment of <em>P. ovale</em>, <em>P. malariae</em>, and, in most regions, <em>P. vivax</em>. (See  <a class="medical medical_review" href="/z/d/html/5706.html" rel="external">"Non-falciparum malaria: P. vivax, P. ovale, and P. malariae"</a>.)</p><p><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> penetrates into most tissues and therefore has a large volume of distribution. As a result, serum drug levels may be maintained for up to two months [<a href="#rid44">44</a>]. Side effects of chloroquine include headaches, dizziness, abdominal discomfort, vomiting, and diarrhea. Chloroquine may also produce pruritus in some patients; this has been noted to occur most frequently in African populations [<a href="#rid45">45</a>]. The pruritus is transient, lasting 48 to 72 hours, and is not responsive to antihistamines.</p><p>Severe adverse reactions are extremely rare. Some are associated only with prolonged use, such as neuromyopathy with long-term prophylaxis and retinopathy with high-dose administration for treatment of rheumatologic diseases (total doses of 1 g/kg or prophylaxis for greater than one year). Rare cases of idiosyncratic reactions, such as erythema multiforme and bone marrow toxicity, have been reported [<a href="#rid46">46</a>]. <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> is only administered orally; intravenous infusion is associated with significant toxicity [<a href="#rid47">47,48</a>].</p><p>Among chloroquine-resistant parasites, there is decreased accumulation of drug within the food vacuole. Mutations in the gene encoding the chloroquine-resistance transporter protein, located in the food vacuole, are associated with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> resistance both in vitro and in vivo [<a href="#rid49">49,50</a>]. Tracing the spread of this gene mutation has led to the current understanding that chloroquine resistance developed independently in Asia, Papua New Guinea, and South America. The chloroquine-resistant gene that emerged in Southeast Asia spread across the Asian continent and reached Africa in the late 1970s [<a href="#rid51">51,52</a>]. Mutations in the homolog of the major multidrug-transporter <em>P. falciparum</em> multidrug-resistance protein-1 (<em>pfmdr1</em>) may modulate the extent of chloroquine resistance as well as resistance to other antimalarials [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Amodiaquine</span><span class="headingEndMark"> — </span>Amodiaquine is similar in structure to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, and there is cross-resistance between the two drugs, although amodiaquine retains some activity against chloroquine-resistant parasites in vivo and in vitro [<a href="#rid54">54-56</a>].</p><p>Amodiaquine is commonly used in malaria-endemic countries as one of the few drugs available to treat chloroquine-resistant infections and is available in coformulation with <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> [<a href="#rid57">57</a>]. Amodiaquine is well tolerated when administered as a single course of treatment over three days. Trials evaluating a three-day treatment course of amodiaquine for uncomplicated malaria noted mild to moderate adverse effects (including nausea, emesis, and pruritus), with no significant hepatotoxicity [<a href="#rid55">55,58</a>]. Adverse event rates were the same as other commonly used antimalarial drugs [<a href="#rid58">58,59</a>]. Declines in neutrophil counts below 1000/mm<sup>3</sup> have been noted with amodiaquine used for therapy of malaria infection, although the clinical significance is not certain [<a href="#rid60">60</a>]. Such neutropenia has not been observed with artesunate-amodiaquine treatment [<a href="#rid61">61</a>].</p><p>Amodiaquine has been taken off the market in the United States due to the risk of toxicity associated with prolonged administration for prophylaxis. The most serious adverse effects of amodiaquine are agranulocytosis and hepatotoxicity, which have been reported in European travelers using amodiaquine to prevent malaria. Based on prescription data from the United Kingdom, the frequency of neutropenia with amodiaquine prophylaxis was 1:2200, while that of hepatic toxicity was 1:15,650 [<a href="#rid62">62</a>]. Case reports have linked such adverse events with total doses of amodiaquine in excess of 1.5 g or with administration over at least one month [<a href="#rid63">63,64</a>].</p><p class="headingAnchor" id="H1659878822"><span class="h3">Piperaquine</span><span class="headingEndMark"> — </span>Piperaquine is a bisquinoline that is closely related to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and amodiaquine. Piperaquine is used in combination with dihydroartemisinin as combination therapy for treatment of malaria; previously, it was used in China and Southeast Asia for the treatment and prevention of malaria during the second half of the 20<sup>th</sup> century. Piperaquine is effective against chloroquine-resistant parasites [<a href="#rid65">65</a>]. The half-life is two to three weeks, which is longer than other drugs that are combined with artemisinin derivatives in artemisinin-based combination therapy; therefore, it provides an extended period of post-treatment prophylaxis [<a href="#rid66">66,67</a>]. Studies suggest piperaquine can cause a prolonged QT interval in the absence of clinical symptoms; the World Health Organization concluded that the risk was likely similar to other commonly used antimalarial drugs [<a href="#rid10">10,68,69</a>].</p><p class="headingAnchor" id="H6"><span class="h2">4-methanolquinolines</span></p><p class="headingAnchor" id="H7"><span class="h3">Quinine and quinidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">Quinine</a> is a derivative from the bark of the South American Cinchona tree and exists in oral and parenteral forms. It is a commonly used parenteral antimalarial drug in malaria-endemic regions. <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">Quinidine</a> is a stereoisomer of quinine available in parenteral formulation and is effective for treatment of severe malaria [<a href="#rid70">70</a>].</p><p>The adverse effects of <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> include a complex of symptoms referred to as cinchonism: tinnitus, nausea, headaches, dizziness, and disturbed vision. These effects are observed to some extent in all patients receiving treatment and typically resolve with cessation of the medication. These symptoms do not warrant change in drug dose. However, toxicity often interferes with compliance in completing the course of therapy. Less commonly, hypersensitivity reaction with bronchospasm and cutaneous manifestations, such as flushing and urticaria, may occur.</p><p><a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">Quinine</a> has a short half-life. When given orally, it must be administered three times per day; when administered together with one week of <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> antibiotics or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, the duration of therapy is three to seven days. The drug should be given for seven days if the infection is acquired in an area where decreased quinine susceptibility has been reported, such as Southeast Asia [<a href="#rid71">71</a>].</p><p>For severe disease, <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> can be administered intravenously or intramuscularly; however, parenteral <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> is the preferred treatment (in the United States, intravenous <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> was discontinued in December 2017) [<a href="#rid72">72</a>]. Intravenous administration of quinidine and quinine should be as an infusion because rapid boluses are associated with hypotension. To hasten parasite clearance time, an initial loading dose of parenteral quinine or quinidine is appropriate if the patient has not received treatment with these agents recently [<a href="#rid73">73</a>]. After initial improvement on parenteral therapy, patients can be switched to oral medication. While therapeutic approaches can include completing a course of oral quinine plus an antibiotic (eg, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>), it may be preferable to give a full course of another oral antimalarial with better tolerability than quinine. (See <a class="local">'Antimicrobials'</a> below and  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p><a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">Quinine</a> and <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a> have a narrow therapeutic window; overdosage may lead to cardiotoxicity, including arrhythmias and hypotension, blindness, or deafness. Quinidine is the most cardiotoxic of these agents: cardiac monitoring including serial blood pressure measurements should always be in place when quinidine is administered to monitor for prolongation of the QT interval and ventricular tachycardia. Blood sugar levels should be monitored with intravenous infusion, as both quinine and quinidine stimulate insulin production [<a href="#rid74">74</a>].</p><p>Reduced <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> efficacy has been described in Southeast Asia [<a href="#rid71">71</a>]. The mechanism for quinine resistance is complex and poorly understood [<a href="#rid75">75</a>]. The combination of quinine with an antibiotic (<a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>) remains effective in areas where decreased quinine susceptibility has been observed.</p><p class="headingAnchor" id="H8"><span class="h3">Mefloquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> is available as an oral formulation and may be used as treatment or prophylaxis for all susceptible malaria species.</p><p>Adverse effects of <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a> include vomiting and dizziness. Like the other drugs in this class, mefloquine can also interfere with cardiac conduction and therefore should not be used in individuals with cardiac conduction abnormalities.</p><p><a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> is contraindicated for individuals with neurologic and psychiatric disorders; those with significant family history of seizures and major psychiatric disorders should also avoid taking mefloquine. Seizures, encephalopathy, and psychosis occur in 0.1 to 5 percent of patients treated for malaria [<a href="#rid76">76</a>]. The extent to which mefloquine is associated with serious neuropsychiatric side effects in the setting of weekly prophylaxis is an area of controversy. The risk of psychosis and panic attacks with mefloquine compared with other antimalarials is increased twofold, although the absolute risk is low (1 to 3 episodes per 1000 person-years of exposure) [<a href="#rid77">77,78</a>]. There is no evidence of an increased risk of depression compared with other antimalarials. Mefloquine users may experience sleep disturbances, including strange dreams and insomnia [<a href="#rid77">77</a>].</p><p>Mefloquine-induced pneumonitis is an infrequently reported but serious adverse event in the setting of both prophylactic and therapeutic use [<a href="#rid79">79-83</a>]. One-third of the patients improved following treatment with corticosteroids, and most patients fully recovered upon discontinuation of the drug.</p><p>Splitting the 25 mg/kg dose into 15 mg/kg and 10 mg/kg over a 6- to 24-hour period may be helpful to reduce mild adverse effects. When used for prophylaxis, it is best started two to three weeks prior to departure to assess tolerability, though side effects can develop long into the prophylactic course or even if it has been well tolerated in the past.</p><p><a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">Mefloquine</a> resistance is found primarily in areas of Southeast Asia. Mefloquine treatment failure is associated with an increase in copy number of <em>pfmdr1</em>, which encodes a protein on the digestive vacuole membrane that appears to play a role in regulating traffic across the membrane [<a href="#rid84">84</a>]. Resistance to the combination of mefloquine plus <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> appears to have emerged in some regions of Southeast Asia [<a href="#rid85">85</a>]. However, mefloquine-susceptible infections may be more common in that region after the introduction of dihydroartemisinin-piperaquine, an artemisinin-based combination therapy for the treatment of malaria [<a href="#rid86">86</a>]. (See <a class="local">'Artemisinin derivatives'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">8-aminoquinolines</span></p><p class="headingAnchor" id="H10"><span class="h3">Primaquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> was the first 8-aminoquinoline in clinical use; its mechanism of action is not known. It is most commonly used to prevent relapse of <em>P. vivax </em>and <em>P. ovale </em>malaria by eliminating dormant hypnozoites and also can be administered for malaria prevention. Primaquine also has activity against the preerythrocytic stage and gametocytes of <em>P. falciparum</em> [<a href="#rid87">87</a>]. It can also be used for prophylaxis when traveling for a short period of time in a malaria-endemic setting.</p><p>Hypnozoite resistance to <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> is difficult to assess. Parasitemia within the first four to six weeks of an initial infection may be due to failure of the blood stage treatment, inadequate adherence, or primaquine treatment failure.</p><p>As part of a malaria elimination campaign, the World Health Organization suggests consideration of a single dose of <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> following an artemisinin-based combination therapy (ACT) regimen to reduce gametocyte carriage [<a href="#rid21">21</a>]. A single low dose is believed to be safe even in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. While ACTs have some activity against gametocytes, the addition of primaquine may further shorten an individual's period of infectivity [<a href="#rid88">88,89</a>].</p><p><a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">Primaquine</a> may cause gastrointestinal upset that can be minimized if taken with food. </p><p class="headingAnchor" id="H3095959625"><span class="h3">Tafenoquine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">Tafenoquine</a> is a long-acting 8-aminoquinoline that targets <em>P. vivax</em> hypnozoites. It received US Food and Drug Administration (FDA) approval in July 2018 for single-dose prevention of <em>P. vivax</em> relapse and for prophylaxis of malaria, including <em>P. falciparum</em> and <em>P. vivax</em>. It can be used to prevent malaria prior to and during travel, or it can be administered as an antirelapse therapy after travel to a malaria-endemic area.</p><p class="headingAnchor" id="H4144204985"><span class="h3">Adverse effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolytic anemia</strong> − Both <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> can cause hemolytic anemia in patients with G6PD deficiency; these medications may be used only if G6PD deficiency has been excluded. </p><p></p><p class="bulletIndent1">There are theoretic concerns that the risk of hemolysis in patients may be more severe with <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> (given its long half-life) than with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>. For patients with mild G6PD deficiency, primaquine dosing may be modified if close medical supervision is available. (See  <a class="medical medical_review" href="/z/d/html/5706.html" rel="external">"Non-falciparum malaria: P. vivax, P. ovale, and P. malariae", section on 'Antirelapse agents'</a>.)</p><p></p><p class="bulletIndent1">Both <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> and <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> are contraindicated in pregnancy (since the G6PD status of the fetus cannot be determined). Primaquine is contraindicated for infants &lt;6 months old as well as women who are breastfeeding infants &lt;6 months old [<a href="#rid10">10</a>]. Tafenoquine is FDA approved for adults and adolescents (16 years and older). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arrhythmia</strong> − Electrocardiogram monitoring is warranted when using <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> in patients with cardiac disease, long QT syndrome, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (&lt;50 beats per minute) and during concomitant administration with QT interval-prolonging agents [<a href="#rid90">90</a>]. </p><p></p><p class="headingAnchor" id="H12"><span class="h1">ANTIFOLATES</span><span class="headingEndMark"> — </span>Antifolates include sulfonamides, <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a>, proguanil, and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>. These drugs act synergistically to target enzymes involved in folate synthesis, a pathway required for parasite DNA synthesis [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Sulfadoxine-pyrimethamine</span><span class="headingEndMark"> — </span>Sulfadoxine and <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> target enzymes involved in folate synthesis; pyrimethamine targets dihydrofolate reductase (DHFR), and sulfadoxine acts on dihydropteroate synthase (DHPS). Sulfadoxine-pyrimethamine is available in a fixed-dose tablet; because the components act on enzymes in the same pathway, it is not considered a combination therapy.</p><p>Mild adverse effects include gastrointestinal upset and headache. Mild bone marrow suppression may occur, and sulfadoxine can precipitate hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Severe cutaneous toxicity due to the sulfa moiety can occur, including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrosis [<a href="#rid92">92,93</a>].</p><p>Resistance to sulfadoxine-pyrimethamine occurs via mutations in the target enzymes DHFR and DHPS. <em>P. falciparum</em> resistance to sulfadoxine-pyrimethamine is widespread in most malaria-endemic regions. The use of sulfadoxine-pyrimethamine is usually restricted to the prevention of malaria in pregnant women in malaria-endemic countries. Due to high levels of resistance, especially in eastern and southern Africa, uncertainty regarding its effectiveness has been raised [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Atovaquone-proguanil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> interferes with two separate pathways involved in the biosynthesis of pyrimidines, which are essential for nucleic acid replication. <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> blocks the parasite mitochondrial electron transport chain, and proguanil inhibits parasite dihydrofolate reductase through its active metabolite, cycloguanil. Proguanil also appears to act via a direct mechanism outside the folate pathway, enhancing atovaquone's mitochondrial membrane toxicity [<a href="#rid95">95,96</a>].</p><p>Adverse effects include abdominal pain, vomiting, diarrhea, headache, and pruritus. Among adults in Thailand, mild asymptomatic increases in transaminases were observed shortly after initiating therapy, although they normalized within two weeks [<a href="#rid97">97,98</a>].</p><p>Resistance to <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">atovaquone</a> is mediated by mutations in the cytochrome b gene. The polymorphism associated with resistance has been found in parasite populations even in the absence of drug pressure and can arise rapidly when the drug is used [<a href="#rid99">99,100</a>]. However, initial studies suggest that atovaquone-resistant parasites cannot be transmitted through the mosquito [<a href="#rid101">101</a>]. The combination retains excellent clinical efficacy for treatment and prevention throughout the world even in the presence of antifolate resistance [<a href="#rid102">102,103</a>].</p><p class="headingAnchor" id="H15"><span class="h1">ANTIMICROBIALS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, and <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> target prokaryotic protein synthesis. In malaria parasites, these drugs appear to target the apicoplast, an organelle derived from prokaryotic ancestors [<a href="#rid91">91</a>]. Antimicrobials have relatively slow antimalarial activity because they exert their toxic effects in the subsequent cycle of cell division [<a href="#rid91">91,104</a>]. They are typically paired with fast-acting antimalarials (usually <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a>). Doxycycline has a longer half-life than tetracycline so is used more commonly. Resistance has not been detected to tetracycline, doxycycline, or clindamycin.</p><p>Adverse effects are common with the tetracyclines and interfere with adherence. Gastrointestinal discomfort and candidiasis are the most frequent complaints. <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> therapy also poses a risk of esophageal ulceration [<a href="#rid105">105</a>]. Photosensitivity can occur with doxycycline, which can be concerning for fair-skinned travelers using it as prophylaxis for travel to the tropics.</p><p>Tetracyclines should not be given to pregnant or lactating women because of the risk of deposition in growing bones and teeth. They may cause permanent tooth discoloration for children less than eight years old if used repeatedly. However, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> binds less readily to calcium than other tetracyclines and may be considered as part of treatment courses for ≤21 days in children of all ages [<a href="#rid106">106</a>]. <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> is the preferred alternative in these groups for treatment; clindamycin should not be used in chemoprophylactic regimens to prevent malaria.</p><p class="headingAnchor" id="H16"><span class="h1">ARTEMISININ DERIVATIVES</span><span class="headingEndMark"> — </span>The artemisinins are derived from the leaves of the Chinese sweet wormwood plant, <em>Artemisia annua</em>. They have been used in China for the treatment of malaria for over 2000 years and came to attention outside of China in the 1970s and 1980s. Artemisinin formulations include artemether, arteether, dihydroartemisinin, and <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a>. They are marketed as part of combination therapy throughout the world.</p><p>Artemisinins appear to act by binding iron, breaking down peroxide bridges, leading to the generation of free radicals that damage parasite proteins [<a href="#rid1">1</a>]. They act rapidly, killing blood stages of all <em>Plasmodium</em> species and reducing the parasite biomass [<a href="#rid2">2</a>]. Artemisinins have the fastest parasite clearance times of any antimalarial [<a href="#rid3">3</a>]. Artemisinins are active against gametocytes, the parasite form that is infectious to mosquitoes, and their use has been associated with reduced malaria transmission when they were introduced in Thailand [<a href="#rid4">4,5</a>].</p><p>Intravenous <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> is first-line therapy for the treatment of severe malaria. It is superior to <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> for treatment of severe malaria with respect to clearing parasitemia and reducing mortality in both children and adults [<a href="#rid6">6,7</a>]. Intravenous artesunate is available for purchase through several major drug distributors [<a href="#rid8">8</a>]. Rectal artesunate is used in remote areas of malaria-endemic countries for stabilizing severely ill patients prior to health facility transport for further management [<a href="#rid9">9</a>].</p><p>Given the short half-life of artemisinins, intravenous therapy must be followed by a longer-acting agent once the patient is able to tolerate oral medication. If used alone (via the parenteral, rectal, or oral route), <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> must be administered for five to seven days. Treatment for less than five days results in recurrent parasitemia several weeks after therapy due to the very short duration of action rather than to artemisinin resistance.</p><p>Individuals with hyperparasitemia treated with intravenous <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> may experience post-treatment hemolysis [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p>Artemisinins are generally well tolerated [<a href="#rid4">4,11,12</a>]. Type 1 hypersensitivity to the artemisinin compounds has been reported (incidence 1:3000) [<a href="#rid13">13</a>]. A large-scale study on the adverse effects of orally administered artemisinins demonstrated transient neurologic abnormalities, including nystagmus and disturbances in balance; these effects resolved without lasting sequelae [<a href="#rid12">12</a>]. Transient neutropenia has been observed in individuals receiving oral <a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">artesunate</a> at doses higher than that typically prescribed [<a href="#rid14">14</a>].</p><p>There have been concerns about the use of artemisinins during the first trimester of pregnancy. Animal studies have suggested that the artemisinin derivatives may be teratogenic during organogenesis [<a href="#rid15">15,16</a>]. A limited number of women in their first trimester have been studied without evidence of adverse events. In observational studies, artemisinins administered in the first trimester have not been associated with adverse pregnancy outcomes [<a href="#rid17">17,18</a>].</p><p>Hemoglobinopathies (such as alpha-globin chain disorders and sickle cell disease) may alter artemisinin metabolism within infected erythrocytes and thus affect parasite clearance, but this has not been shown to be clinically significant [<a href="#rid19">19,20</a>]. Further study of the metabolism of artemisinins in these populations is needed, particularly in regions such as Southeast Asia, where there is artemisinin resistance and hemoglobinopathies such as hemoglobin E are common.</p><p class="headingAnchor" id="H17"><span class="h2">Artemisinin-based combination therapies</span><span class="headingEndMark"> — </span>In general, artemisinins should not be used as a single agent to prevent emergence of drug resistance and to avoid the need for prolonged therapy. Artemisinin-based combination therapy (ACT) combines the highly effective short-acting artemisinins with a longer-acting partner to protect against artemisinin resistance and to facilitate dosing convenience. ACTs are typically administered for three days and are often available in fixed-dose tablets.</p><p>Six ACTs are recommended by the World Health Organization for the treatment of uncomplicated malaria: <a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">artemether-lumefantrine</a>, artesunate-amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine  (<a class="graphic graphic_table graphicRef107438" href="/z/d/graphic/107438.html" rel="external">table 1</a>) [<a href="#rid21">21,22</a>]. Artemether-lumefantrine is the most widely adopted ACT, followed by artesunate-amodiaquine. Dihydroartemisinin-piperaquine is being widely used in research studies and pilot programs for intermittent treatment and targeted parasite elimination programs.</p><p><a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">Artemether-lumefantrine</a> is best absorbed with fat so should be taken with a meal or fatty drink such as milk. In contrast, dihydroartemisinin-piperaquine should not be taken with a high-fat meal, as this increases piperaquine absorption which may alter cardiac conduction and increase the risk of an arrhythmia [<a href="#rid10">10</a>]. Dihydroartemisinin-piperaquine should not be administered to patients at risk for prolonged QT interval.</p><p>Pyronaridine-artesunate is a newer ACT formulation with similar efficacy to <a class="drug drug_general" data-topicid="9066" href="/z/d/drug information/9066.html" rel="external">artemether-lumefantrine</a> and artesunate-mefloquine for treatment of uncomplicated <em>P. falciparum</em> malaria [<a href="#rid23">23-25</a>]. Pyronaridine is active against chloroquine-resistant infections, although there has been concern about the emergence of resistance if used as monotherapy [<a href="#rid26">26,27</a>]. Advantages of pyronaridine include its structural dissimilarity to other antimalarial drugs, long shelf-life, and once-daily dosing.</p><p class="headingAnchor" id="H1137919195"><span class="h2">Artemisinin resistance</span><span class="headingEndMark"> — </span>Reduced susceptibility to artemisinins, as evidenced by delayed parasite clearance time, has been demonstrated in Southeast Asia but not sub-Saharan Africa [<a href="#rid28">28-31</a>]. Point mutations in the kelch protein K13 are associated with this reduced susceptibility [<a href="#rid30">30,32-34</a>]; the underlying mechanism is not known. Many of these mutations have arisen independently in Southeast Asia, but resistance has also spread within the region [<a href="#rid33">33</a>]. Evidence of artemisinin resistance has emerged in sub-Saharan Africa but is not yet widespread [<a href="#rid35">35,36</a>].</p><p>Decreased susceptibility to artemisinins may increase the likelihood of developing resistance to partner drugs. Dihydroartemisinin-piperaquine treatment failures in Cambodia have occurred where artemisinin resistance is emerging [<a href="#rid37">37-39</a>]. The mechanism for piperaquine resistance has not yet been determined; increased copy numbers of <em>plasmepsin 2</em> and <em>plasmepsin 3</em>, two genes that encode proteases that digest hemoglobin, serve as markers for resistance [<a href="#rid40">40,41</a>]. A novel mutation in the <em>pfcrt</em> gene is also associated with decreased piperaquine sensitivity [<a href="#rid42">42</a>].</p><p>Because the artemisinins are the cornerstone of nearly all new combination therapies, the World Health Organization has called for the banning of all manufacturing and distribution of oral artemisinin monotherapy to deter resistance.</p><p class="headingAnchor" id="H21"><span class="h1">DRUG QUALITY</span><span class="headingEndMark"> — </span>Counterfeit and low-quality antimalarial medications are significant concerns worldwide, with implications for treatment failure among individual patients and public health concerns related to development of drug resistance. In surveys of antimalarial medications purchased in Southeast Asia, 30 to 50 percent of medications were counterfeit, containing a subtherapeutic or undetectable amount of active ingredient [<a href="#rid107">107-109</a>]. These samples were purchased in a range of different venues, including informal shops, pharmacies, and hospitals. There is increasing evidence of poor quality and counterfeiting of antimalarial drugs in Africa, especially those purchased outside the formal health care system [<a href="#rid110">110,111</a>].</p><p class="headingAnchor" id="H13746045"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness  (<a class="graphic graphic_figure graphicRef79113" href="/z/d/graphic/79113.html" rel="external">figure 1</a>). Treatment of the acute blood stage infection is necessary for malaria caused by all malaria species. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Artemisinin-based combination therapy combines the highly effective short-acting artemisinins with a longer-acting partner to protect against artemisinin resistance and to facilitate dosing convenience. (See <a class="local">'Artemisinin derivatives'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Quinoline derivatives (<a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, amodiaquine, piperaquine, <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>, <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>, lumefantrine, and halofantrine) have activity against the erythrocytic stage of infection; primaquine also kills intrahepatic forms and gametocytes  (<a class="graphic graphic_figure graphicRef79113" href="/z/d/graphic/79113.html" rel="external">figure 1</a>). Widespread resistance in most malaria-endemic countries has led to decline in use of chloroquine for the treatment of <em>Plasmodium falciparum</em>, although it remains effective for treatment of <em>Plasmodium ovale</em>, <em>Plasmodium malariae</em>, and, in most regions, <em>Plasmodium vivax</em>. (See <a class="local">'Chloroquine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For treatment of infection due to <em>P. vivax </em>or<em> P. ovale</em>, terminal prophylaxis with <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a> or <a class="drug drug_general" data-topicid="118521" href="/z/d/drug information/118521.html" rel="external">tafenoquine</a> is required; otherwise, hypnozoites can remain dormant in the liver for months to years after infection. (See <a class="local">'Introduction'</a> above and <a class="local">'8-aminoquinolines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antifolates (sulfonamides, <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a>, proguanil, and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>) act synergistically to target enzymes involved in folate synthesis, a pathway required for parasite DNA synthesis. <a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> interferes with two separate pathways involved in the biosynthesis of pyrimidines essential for nucleic acid replication. (See <a class="local">'Antifolates'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424:957.</a></li><li><a class="nounderline abstract_t">White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413.</a></li><li><a class="nounderline abstract_t">White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994; 88 Suppl 1:S41.</a></li><li><a class="nounderline abstract_t">Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363:9.</a></li><li><a class="nounderline abstract_t">Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356:297.</a></li><li><a class="nounderline abstract_t">Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717.</a></li><li><a class="nounderline abstract_t">Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647.</a></li><li class="breakAll">Intravenous Artesunate for Treatment of Severe Malaria in the United States. https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html (Accessed on July 23, 2021).</li><li><a class="nounderline abstract_t">Gomes M, Ribeiro I, Warsame M, et al. Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies. BMC Infect Dis 2008; 8:39.</a></li><li class="breakAll">World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on January 23, 2022).</li><li><a class="nounderline abstract_t">Myint HY, Tipmanee P, Nosten F, et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 2004; 98:73.</a></li><li><a class="nounderline abstract_t">Price R, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60:547.</a></li><li><a class="nounderline abstract_t">Leonardi E, Gilvary G, White NJ, Nosten F. Severe allergic reactions to oral artesunate: a report of two cases. Trans R Soc Trop Med Hyg 2001; 95:182.</a></li><li><a class="nounderline abstract_t">Bethell D, Se Y, Lon C, et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis 2010; 51:e105.</a></li><li><a class="nounderline abstract_t">Clark RL, Lerman SA, Cox EM, et al. Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res B Dev Reprod Toxicol 2008; 83:397.</a></li><li><a class="nounderline abstract_t">Clark RL, Arima A, Makori N, et al. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B Dev Reprod Toxicol 2008; 83:418.</a></li><li><a class="nounderline abstract_t">Moore KA, Simpson JA, Paw MK, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis 2016; 16:576.</a></li><li><a class="nounderline abstract_t">Dellicour S, Desai M, Aol G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. Malar J 2015; 14:461.</a></li><li><a class="nounderline abstract_t">Adjei GO, Goka BQ, Enweronu-Laryea CC, et al. A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria. Malar J 2014; 13:369.</a></li><li><a class="nounderline abstract_t">Sugiarto SR, Moore BR, Makani J, Davis TME. Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review. Clin Infect Dis 2018; 66:799.</a></li><li class="breakAll">World Health Organization. Guidelines for malaria, 25 November 2022. https://www.who.int/publications/i/item/guidelines-for-malaria (Accessed on November 30, 2022).</li><li class="breakAll">World Health Organization. The use of artesunate-pyronaridine for the treatment of uncomplicated malaria. https://www.who.int/publications-detail/use-of-artesunate-pyronaridine-for-the-treatment-of-uncomplicated-malaria (Accessed on February 24, 2020).</li><li><a class="nounderline abstract_t">Ramharter M, Kurth F, Schreier AC, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 2008; 198:911.</a></li><li><a class="nounderline abstract_t">Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010; 375:1457.</a></li><li><a class="nounderline abstract_t">Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012; 366:1298.</a></li><li><a class="nounderline abstract_t">Ringwald P, Bickii J, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 1998; 26:946.</a></li><li><a class="nounderline abstract_t">Vivas L, Rattray L, Stewart L, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop 2008; 105:222.</a></li><li><a class="nounderline abstract_t">Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619.</a></li><li><a class="nounderline abstract_t">Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455.</a></li><li><a class="nounderline abstract_t">Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014; 371:411.</a></li><li class="breakAll">World Health Organization. World Malaria Report 2018. https://apps.who.int/iris/handle/10665/275867 (Accessed on August 11, 2021).</li><li><a class="nounderline abstract_t">Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014; 505:50.</a></li><li><a class="nounderline abstract_t">Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis 2015; 211:670.</a></li><li><a class="nounderline abstract_t">Phyo AP, Ashley EA, Anderson TJ, et al. Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors. Clin Infect Dis 2016; 63:784.</a></li><li><a class="nounderline abstract_t">Balikagala B, Fukuda N, Ikeda M, et al. Evidence of Artemisinin-Resistant Malaria in Africa. N Engl J Med 2021; 385:1163.</a></li><li><a class="nounderline abstract_t">Uwimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis 2021; 21:1120.</a></li><li><a class="nounderline abstract_t">Leang R, Barrette A, Bouth DM, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 2013; 57:818.</a></li><li><a class="nounderline abstract_t">Saunders DL, Vanachayangkul P, Lon C, et al. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014; 371:484.</a></li><li><a class="nounderline abstract_t">Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016; 16:357.</a></li><li><a class="nounderline abstract_t">Amato R, Pearson RD, Almagro-Garcia J, et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis 2018; 18:337.</a></li><li><a class="nounderline abstract_t">Witkowski B, Duru V, Khim N, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis 2017; 17:174.</a></li><li><a class="nounderline abstract_t">Agrawal S, Moser KA, Morton L, et al. Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. J Infect Dis 2017; 216:468.</a></li><li><a class="nounderline abstract_t">White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.</a></li><li><a class="nounderline abstract_t">Warhurst DC, Steele JC, Adagu IS, et al. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 2003; 52:188.</a></li><li><a class="nounderline abstract_t">EKPECHI OL, OKORO AN. A PATTERN OF PRURITUS DUE TO CHLOROQUINE. Arch Dermatol 1964; 89:631.</a></li><li><a class="nounderline abstract_t">Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27:25.</a></li><li><a class="nounderline abstract_t">Severe and complicated malaria. World Health Organization Malaria Action Programme. Trans R Soc Trop Med Hyg 1986; 80 Suppl:3.</a></li><li><a class="nounderline abstract_t">SCOTT V. Single intravenous injections of chloroquine in the treatment of falciparum malaria: toxic and immediate therapeutic effects in 110 cases. Am J Trop Med Hyg 1950; 30:503.</a></li><li><a class="nounderline abstract_t">Djimdé A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001; 344:257.</a></li><li><a class="nounderline abstract_t">Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6:861.</a></li><li><a class="nounderline abstract_t">Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770.</a></li><li><a class="nounderline abstract_t">Wootton JC, Feng X, Ferdig MT, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002; 418:320.</a></li><li><a class="nounderline abstract_t">Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27:594.</a></li><li><a class="nounderline abstract_t">Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002; 298:210.</a></li><li><a class="nounderline abstract_t">Olliaro P, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst Rev 2003; :CD000016.</a></li><li><a class="nounderline abstract_t">Venkatesan M, Gadalla NB, Stepniewska K, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg 2014; 91:833.</a></li><li class="breakAll">World Health Organization. WHO List of Prequalified Medicinal Products. http://www.who.int/prequal/query/ProductRegistry.aspx (Accessed on February 13, 2009).</li><li><a class="nounderline abstract_t">Olliaro P, Nevill C, LeBras J, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 1996; 348:1196.</a></li><li><a class="nounderline abstract_t">Massaga JJ, Lusingu JP, Makunde R, et al. Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania. Tanzan J Health Res 2008; 10:144.</a></li><li><a class="nounderline abstract_t">Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359:1365.</a></li><li><a class="nounderline abstract_t">Zwang J, Ndiaye JL, Djimdé A, et al. Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa. Malar J 2012; 11:25.</a></li><li><a class="nounderline abstract_t">Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990; 83:82.</a></li><li><a class="nounderline abstract_t">Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; 1:411.</a></li><li><a class="nounderline abstract_t">Neftel KA, Woodtly W, Schmid M, et al. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986; 292:721.</a></li><li><a class="nounderline abstract_t">Keating GM. Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs 2012; 72:937.</a></li><li><a class="nounderline abstract_t">Tarning J, Zongo I, Somé FA, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012; 91:497.</a></li><li><a class="nounderline abstract_t">Hung TY, Davis TM, Ilett KF, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004; 57:253.</a></li><li><a class="nounderline abstract_t">Manning J, Vanachayangkul P, Lon C, et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother 2014; 58:6056.</a></li><li><a class="nounderline abstract_t">Baiden R, Oduro A, Halidou T, et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar J 2015; 14:160.</a></li><li><a class="nounderline abstract_t">Phillips RE, Warrell DA, White NJ, et al. Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. N Engl J Med 1985; 312:1273.</a></li><li><a class="nounderline abstract_t">Pukrittayakamee S, Supanaranond W, Looareesuwan S, et al. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg 1994; 88:324.</a></li><li><a class="nounderline abstract_t">Chaccour C, Rabinovich NR. Advancing the repurposing of ivermectin for malaria. Lancet 2019; 393:1480.</a></li><li><a class="nounderline abstract_t">Lesi A, Meremikwu M. High first dose quinine regimen for treating severe malaria. Cochrane Database Syst Rev 2004; :CD003341.</a></li><li><a class="nounderline abstract_t">Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) 1986; 292:1319.</a></li><li><a class="nounderline abstract_t">Ferdig MT, Cooper RA, Mu J, et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol 2004; 52:985.</a></li><li><a class="nounderline abstract_t">Deen JL, von Seidlein L, Dondorp A. Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop Med Int Health 2008; 13:1111.</a></li><li><a class="nounderline abstract_t">Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297:2251.</a></li><li><a class="nounderline abstract_t">Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004; 27:203.</a></li><li><a class="nounderline abstract_t">Katsenos S, Psathakis K, Nikolopoulou MI, Constantopoulos SH. Mefloquine-induced eosinophilic pneumonia. Pharmacotherapy 2007; 27:1767.</a></li><li><a class="nounderline abstract_t">Soentjens P, Delanote M, Van Gompel A. Mefloquine-induced pneumonitis. J Travel Med 2006; 13:172.</a></li><li><a class="nounderline abstract_t">Inoue T, Tanaka E, Sakuramoto M, et al. [Case of drug-induced pneumonia possibly due to mefloquine (antimalarial drug)]. Nihon Kokyuki Gakkai Zasshi 2005; 43:103.</a></li><li><a class="nounderline abstract_t">Udry E, Bailly F, Dusmet M, et al. Pulmonary toxicity with mefloquine. Eur Respir J 2001; 18:890.</a></li><li class="breakAll">Food and Drug Administration. Postmarketing Reviews - Volume 1, Number 4, Summer 2008. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm120613.htm (Accessed on September 19, 2008).</li><li><a class="nounderline abstract_t">Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438.</a></li><li><a class="nounderline abstract_t">Rogers WO, Sem R, Tero T, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 2009; 8:10.</a></li><li><a class="nounderline abstract_t">Chaorattanakawee S, Saunders DL, Sea D, et al. Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance. Antimicrob Agents Chemother 2015; 59:4631.</a></li><li><a class="nounderline abstract_t">Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003; 37:1659.</a></li><li><a class="nounderline abstract_t">Shekalaghe S, Drakeley C, Gosling R, et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2007; 2:e1023.</a></li><li><a class="nounderline abstract_t">Sutanto I, Suprijanto S, Kosasih A, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 2013; 56:685.</a></li><li class="breakAll">US Food and Drug Administration. Primaquine: Phosphate Tablets, USP. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/008316s021lbl.pdf (Accessed on April 29, 2015).</li><li><a class="nounderline abstract_t">Goodman CD, Su V, McFadden GI. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 2007; 152:181.</a></li><li><a class="nounderline abstract_t">Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35:451.</a></li><li><a class="nounderline abstract_t">Gimnig JE, MacArthur JR, M'bang'ombe M, et al. Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 2006; 74:738.</a></li><li><a class="nounderline abstract_t">ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 2007; 297:2603.</a></li><li><a class="nounderline abstract_t">Fidock DA, Nomura T, Wellems TE. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol 1998; 54:1140.</a></li><li><a class="nounderline abstract_t">Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43:1334.</a></li><li class="breakAll">GlaxoSmithKline. Malarone prescribing information. 2008.</li><li><a class="nounderline abstract_t">Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999; 60:533.</a></li><li><a class="nounderline abstract_t">Happi CT, Gbotosho GO, Folarin OA, et al. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar J 2006; 5:82.</a></li><li><a class="nounderline abstract_t">Schwöbel B, Alifrangis M, Salanti A, Jelinek T. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2003; 2:5.</a></li><li><a class="nounderline abstract_t">Goodman CD, Siregar JE, Mollard V, et al. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science 2016; 352:349.</a></li><li><a class="nounderline abstract_t">Nakato H, Vivancos R, Hunter PR. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. J Antimicrob Chemother 2007; 60:929.</a></li><li><a class="nounderline abstract_t">Krudsood S, Patel SN, Tangpukdee N, et al. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2007; 76:655.</a></li><li><a class="nounderline abstract_t">Dahl EL, Shock JL, Shenai BR, et al. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 2006; 50:3124.</a></li><li><a class="nounderline abstract_t">Al-Mofarreh MA, Al Mofleh IA. Esophageal ulceration complicating doxycycline therapy. World J Gastroenterol 2003; 9:609.</a></li><li class="breakAll">American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li><li><a class="nounderline abstract_t">Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004; 9:1241.</a></li><li><a class="nounderline abstract_t">Newton P, Proux S, Green M, et al. Fake artesunate in southeast Asia. Lancet 2001; 357:1948.</a></li><li><a class="nounderline abstract_t">Newton PN, Fernández FM, Plançon A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008; 5:e32.</a></li><li><a class="nounderline abstract_t">Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One 2008; 3:e2132.</a></li><li><a class="nounderline abstract_t">Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012; 12:488.</a></li></ol></div><div id="topicVersionRevision">Topic 468 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12931192" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Artemisinins target the SERCA of Plasmodium falciparum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9210658" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053024" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723987" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Artesunate combinations for treatment of malaria: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11071185" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125588" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21062666" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21062666" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18373841" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18373841" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14964805" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A systematic overview of published antimalarial drug trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348227" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11355556" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Severe allergic reactions to oral artesunate: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21070142" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702118" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702116" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Artesunate: developmental toxicity and toxicokinetics in monkeys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26869377" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26581434" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25236838" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370347" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370347" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370347" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18694333" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20417857" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22475593" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pyronaridine-artesunate versus mefloquine plus artesunate for malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9564481" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279817" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064625" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Evidence of artemisinin-resistant malaria in western Cambodia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19641202" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Artemisinin resistance in Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075834" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Spread of artemisinin resistance in Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075834" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Spread of artemisinin resistance in Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24352242" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A molecular marker of artemisinin-resistant Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180241" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27313266" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551228" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Evidence of Artemisinin-Resistant Malaria in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33864801" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23208711" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25075853" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dihydroartemisinin-piperaquine failure in Cambodia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26774243" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398391" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27818097" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28931241" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8703186" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The treatment of malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12837731" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14107655" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A PATTERN OF PRURITUS DUE TO CHLOROQUINE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14720085" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antimalarial drug toxicity: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523867" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Severe and complicated malaria. World Health Organization Malaria Action Programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15425740" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Single intravenous injections of chloroquine in the treatment of falciparum malaria: toxic and immediate therapeutic effects in 110 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172152" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A molecular marker for chloroquine-resistant falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11090624" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11517439" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chloroquine-resistant malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12124623" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996622" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Transporters involved in resistance to antimalarial drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364805" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12804382" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Amodiaquine for treating malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25048375" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25048375" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8898036" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Systematic review of amodiaquine treatment in uncomplicated malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19024339" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978332" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22276858" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2138674" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2868340" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082410" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Amodiaquine induced agranulocytosis and liver damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22515619" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258469" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998421" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092702" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25885858" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim®(dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3887162" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7974679" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30878223" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Advancing the repurposing of ivermectin for malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266481" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : High first dose quinine regimen for treating severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3085830" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15130119" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Dissecting the loci of low-level quinine resistance in malaria parasites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657092" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519415" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Controversies and misconceptions in malaria chemoprophylaxis for travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14756582" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18041895" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mefloquine-induced eosinophilic pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16706949" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Mefloquine-induced pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15770942" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : [Case of drug-induced pneumonia possibly due to mefloquine (antimalarial drug)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11757641" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pulmonary toxicity with mefloquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11757641" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pulmonary toxicity with mefloquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288742" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138388" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26014942" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14689349" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Primaquine for prevention of malaria in travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17925871" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175563" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23175563" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17289168" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The effects of anti-bacterials on the malaria parasite Plasmodium falciparum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2939735" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16687672" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17579229" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855645" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348748" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A mechanism for the synergistic antimalarial action of atovaquone and proguanil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348748" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A mechanism for the synergistic antimalarial action of atovaquone and proguanil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348225" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17020611" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665429" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27081071" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848375" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426165" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940111" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12632529" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Esophageal ulceration complicating doxycycline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12632529" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Esophageal ulceration complicating doxycycline therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598255" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11425421" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Fake artesunate in southeast Asia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18271620" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18461128" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Antimalarial drug quality in the most severely malarious parts of Africa - a six country study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22632187" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
